How artificial intelligence is revealing thousands of previously unknown bacterial antiviral defense systems, and why they could become the next generation of biotechnology tools TL;DR: Two recently published science...read more
Features and insights
Tempus Acquires Personalis and Raises the Stakes in the MRD Market
The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
The Dangerous Bet Behind Big Pharma’s Silence
Why dismantling America’s biomedical innovation engine is a long-term threat to the very industry staying quiet about it. A recent piece by Steven Usdain, which was also highlighted by Holden Thorp, got me thinking: are...read more
When “Anonymous” Isn’t: The UK Biobank Data Exposure and the Limits of Health Data Privacy
The UK Biobank data exposure highlights a growing risk in modern health research: sensitive data is not only vulnerable to breaches, but to systemic leakage through normal scientific practices. This raises urgent...read more
From Experimentation to Execution: How 2025 Reset the Trajectory of Healthcare and What 2026 Will Demand
TL;DR 2025 shifted healthcare from experimentation to execution AI moved from tools to infrastructure 2026 will reward disciplined execution over vision Why this matters for precision medicine + generative AI This...read more
Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues
Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of...read more
New Therapy Potential of Targeted Protein Degradation
New approaches in drug discovery currently focus on the concept of a „magic bullet“ molecule. One that precisely targets an intended pharmacological role without off-target actions or unwanted side-effects. Traditional...read more
BEVIMI Launches: A New Bid to Bring Pharma-Grade Rigor to Brain Health
This past week, BEVIMI was officially announced. This new company aims to bring pharmaceutical-style rigor to the consumer brain-health market. Headquartered in Greenwich, Connecticut and led by co-founders Paul...read more
Why Are We Still Talking About Data Infrastructure for Life Sciences in 2025?
“In my twenty-five years in the Life Sciences industry, I’ve observed countless organizations adopt, revise, dismantle, and rebuild their data infrastructure.” While the rapid advancements of data technology certainly...read more
Why Most Startups Fail: The Brutal Truth and How to Beat the Odds
Launching a startup is exhilarating—a whirlwind of big ideas, bold moves, sleepless nights, and passionate pitches. But behind the scenes, the harsh reality remains: Most startups fail. Depending on which study you...read more
